DOCSLIB.ORG

Anthelmintica / Flukicides Order Formula Name Chemical Name Offer No

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Anthelmintica / Flukicides Order Formula Name Chemical Name Offer No WITEGA Laboratorien Berlin-Adlershof GmbH James-Franck-Strasse 4 D-12489 Berlin www.auftragssynthese.com [email protected] Tel. +49(0) 30 6392 2195 Fax +49(0) 30 6392 2041 June 09, 2021 Anthelmintica / Flukicides Order Formula Name Chemical Name Offer No. CAS Number BI002 Thiabendazole-13C6 2-Thiazol-4-yl-1H-[3a,4,5,6,7,7a-13C] 10 mg benzimidazole 25 mg - BI001 Cl N Triclabendazole-D3 5-Chloro-6-(2,3-dichloro-phenoxy)-2- 10 mg S (methyl-D3-thio)-1H-benzoimidazole 50 mg N CD Cl O H 3 Cl 1353867-93-2 BI013 Cl N Triclabendazole 5-Chloro-6-(2,3-dichloro-phenoxy)-2- 50 mg S methylthio-1H-benzoimidazole 100 mg N CH Cl O H 3 Cl 68786-66-3 BI074 Triclabendazole-D3 5-Chloro-6-(2,3-dichloro phenoxy)-2- 25 mg sulfone methyl-D3-sulfonyl-1H-benzimidazole - BI014 Cl N O Triclabendazole sulfone 5-Chloro-6-(2,3-dichloro-phenoxy)-2- 10 mg S CH 3 methylsulfo-nyl-1H-benzoimidazole 50 mg N O Cl O H 106791-37-1 100 mg Cl BI075 Triclabendazole-D3 5-Chloro-6-(2,3-dichloro-phenoxy)-2- 25 mg sulfoxide methyl-D3-sulfinyl-1H-benzimidazole - BI015 Cl N O Triclabendazole 5-Chloro-6-(2,3-dichloro-phenoxy)-2- 10 mg S sulfoxide methylsulfi-nyl-1H-benzoimidazole 50 mg N Cl O CH H 3 100 mg Cl 100648-13-3 H BI016 Cl N Ketotriclabendazole 5-Chloro-6-(2,3-dichloro-phenoxy)-1,3- 10 mg O dihydro-benzoimidazol-2-one 50 mg N Cl O H 100 mg Cl 1201920-88-8 BI036 Cl N Aminotriclabendazole 5-Chloro-6-(2,3-dichlo-ro-phenoxy)- 25 mg hydrochloride 1H-benzo-imidazol-2-ylamine NH2 50 mg O N hydrochloride H H Cl Cl Cl WITEGA Laboratorien Berlin-Adlershof GmbH page 1 of 104 Anthelmintica / Flukicides 1448346-37-9 BI072 Hydroxytriclabendazo- 2,3-Dichloro-4-{[6-chloro-2-(methyl-D3- 10 mg le-D3 thio)-1H-benzimidazol-5- 25 mg yl]oxy}phenole - BI049 HO Cl N Hydroxytriclabenda-zole 2,3-Dichloro-4-(6-chloro-2- 10 mg S methylsulfanyl-3H-benzoimidazol-5- 25 mg Cl N CH yloxy)-phenol O 3 109536-21-2 H Cl BI003 H 5-Hydroxythiabendazole 2-Thiazol-4-yl-1H-benzoimidazol-5-ol 10 mg HO N S 25 mg N N 948-71-0 50 mg D BI037 D H Cambendazole-D7 (2-Thiazol-4-yl-1H-benzimidazol-5-yl)- 25 mg O N N D S carbamic acid isopropyl-D7- ester 50 mg D O D D N N H D 1228182-48-6 BI038 H Cambendazole (2-Thiazol-4-yl-1H-benzimidazol-5-yl)- 25 mg Me O N N S carbamic acid isopropyl ester 50 mg Me O N N H 26097-80-3 13 BI064 H O 2-Aminoflubendazole- 2-Amino-5-(4-fluoroben-zoyl- C6)-1H- 10 mg 13 H C N 13C6 benzimi-dazole 13C 13C 25 mg NH2 13C 13C F 13C H N H - H BI004 O 2-Aminoflubendazole 2-Amino-5-(4-fluorben-zoyl)-1H- 10 mg N benzoimidazol 50 mg NH 2 100 mg F N H 82050-13-3 BI020 O Albendazole-D3 (5-Propylsulfanyl-1H-benzoimidazol-2- 10 mg S N O H C yl)-carbamic acid methyl-D3 ester 3 N CD 50 mg H 3 N 100 mg H 1353867-92-1 BI067 O CH3 Albendazole (5-Propylsulfanyl-1H-benzimidazol-2- 100 mg S N O yl]-carbamic acid methyl ester H3C NH N H 54965-21-8 BI076 Albendazole-2-amino- 2-Amino-5-propylsulfo-nyl-1H- 50 mg sulfone benzimidazole 80983-34-2 BI005 O Albendazole-2-ami- 5-(Propane-1-sulfonyl)-1H- 10 mg HCl benzoimidazol-2-ylamine S N nosulfone hydrochlo- 50 mg H C hydrochloride 3 O NH ride 2 100 mg N - H WITEGA Laboratorien Berlin-Adlershof GmbH page 2 of 104 Anthelmintica / Flukicides Albendazole-2- BI035 O O HCl 2-Amino-5-propyl-D3- 25 mg D S aminosulfone-D3 N sulfonylbenzimidazole hydrochloride 50 mg D NH hydrochloride D 2 N H 1435902-07-0 O BI022 O Albendazole sulfone-D3 [5-(Propane-1-sulfonyl)-1H- 10 mg S O benzoimidazol-2-yl]-carbamic acid N 50 mg H3C O N CD methyl-D3 ester H 3 N 1448345-60-5 100 mg H BI006 O O Albendazole sulfone [5-(Propane-1-sulfonyl)-1H- 10 mg S N O benzoimidazol-2-yl]-carbamic acid 50 mg H3C O N CH3 methyl ester H N 100 mg H 75184-71-3 BI021 O O Albendazole sulfoxi-de- [5-(Propane-1-sulfinyl)-1H- 10 mg S N O D3 H C benzoimidazol-2-yl]-carbamic acid 50 mg 3 N CD Ricobendazole-D3 H 3 methyl-D3 ester N 100 mg H 1448346-38-0 BI007 O O Albendazole sulfoxide [5-(Propane-1-sulfinyl)-1H- 10 mg S N O Ricobendazole benzoimidazol-2-yl]-carbamic acid H3C 50 mg N CH3 methyl ester H N 100 mg H 54029-12-8 H O 13 BI063 Mebendazole-amine- 2-Amino-5-(benzoyl- C6)-1H- 10 mg 13 C N 13C6 H 13C 13C benzimidazole 25 mg NH2 13C 13C H 13C H N H - H BI008 O Mebendazole-amine 2-Amino-5-benzoyl-1H-benzoimidazole 10 mg HMEB N 50 mg NH2 N 100 mg H 52329-60-9 BI028 O Mebendazole-D3 (5-Benzoyl-1H-benzo-imidazol-2-yl)- 50 mg N carbamic acid methyl-D3 ester H 100 mg N CD3 N O H O 1173021-87-8 OH BI009 O 5-Hydroxymebendazole [5-(Hydroxyphenylmethyl)-1H- 10 mg (RMEB) N O benzoimidazol-2-yl] carbamic acid 50 mg N CH H 3 methyl ester N 60254-95-7 100 mg H BI029 OH O 5-Hydroxymebenda- [5-(Hydroxy-phenyl-methyl)-1H- 25 mg zole-D3 N O benzimidazol-2-yl]-carbamic acid 50 mg N CD methyl-D3 ester H 3 N 1173020-86-4 H BI010 O Flubendazole [5-(4-Fluoro-benzoyl)-1H- 50 mg N H benzoimidazol-2-yl]-carbamic acid 100 mg N O CH 3 methyl ester F N O H 31430-15-6 BI027 O Flubendazole-D3 [5-(4-Fluoro-benzoyl)-1H- 50 mg N H benzoimidazol-2-yl]-carbamic acid N 100 mg methyl-D3 ester F N O H O CD 3 1173021-08-3 WITEGA Laboratorien Berlin-Adlershof GmbH page 3 of 104 Anthelmintica / Flukicides BI050 OH O Hydroxyflubendazole {5-[(4-Fluoro-phenyl)-hydroxy-methyl]- 50 mg N O 1H-benzoimidazol-2-yl}-carbamic acid 100 mg N CH H 3 methyl ester F N H 82050-12-2 BI011 O Oxfendazole (5-Benzenesulfinyl-1H-benzoimidazol- 50 mg S N H (Fenbendazole 2-yl)-carbamic acid methyl ester N O 100 mg CH3 sulfoxide) N O H 53716-50-0 BI025 O Oxfendazole-D3 (5-Benzenesulfinyl-1H-benzoimidazol- 10 mg S H (Fenbendazole N 2-yl)-carbamic acid methyl-D3 ester 50 mg N O sulfoxide-D3) CD3 N 100 mg O H 1228182-54-4 BI012 O O Fenbendazole sulfone (5-Benzenesulfonyl-1H-benzoimidazol- 10 mg S H N 2-yl)-carbamic acid methyl ester N O 50 mg CH3 N O 100 mg H 54029-20-8 BI026 O O Fenbendazole sulfone- (5-Benzenesulfonyl-1H-benzoimidazol- 10 mg S H D3 N 2-yl)-carbamic acid methyl-D3 ester 50 mg N O CD3 N 100 mg O H 1228182-49-7 BI024 S N H Fenbendazole-D3 (5-Phenylsulfanyl-1H-benzoimidazol-2- 10 mg N O CD 3 yl)-carbamic acid 50 mg N O methyl-D3 ester H 1228182-47-5 100 mg BI034 S N Fenbendazole-amine 5-Phenylsulfanyl-1H-benzoimidazol-2- 50 mg NH hydrochloride 2 ylamine hydrochloride 100 mg N H HCl 1448346-29-9 BI060 O Hydroxyfenbendazole- [5-(4-Hydroxy-phenyl-sulfanyl)-1H- 50 mg S N O D3 hydrate (see Data NH CD3 benzo-imidazol-2-yl]-carbamic acid 100 mg HO N Sheet) H methyl-D3 ester hydrate (see Data x mole H2O Sheet) 1596803-40-5 (anhydrous) BI059 O Hydroxyfenbendazole [5-(4-Hydroxy-phenyl-sulfanyl)-1H- 50 mg S N O hydrate (see Data NH CH3 benzo-imidazol-2-yl]-carbamic acid 100 mg HO N Sheet) H methyl ester hydrate (see Data Sheet) x mole H2O 72447-64-4 (anhydrous) O H Luxabendazole-D3 BI055 O N 4-Fluoro-benzenesulfo-nic acid 2- 25 mg S H N CD O 3 methoxy-D3-carbonylamino-3H- 50 mg N O benzoimidazol-5-yl ester F O 1448346-27-7 O H Luxabendazole BI054 O N 4-Fluoro-benzenesulfo-nic acid 2- 50 mg S H N CH O 3 methoxycarbo-nylamino-3H-benzoimi- 100 mg N O dazol-5-yl ester F O 90509-02-7 S N Cyclopentylalbendazole BI017 H (5-Cyclopentanesulfa-nyl-1H- 50 mg N CH 3 benzoimidazol-2-yl)-carbamic acid N O 100 mg H 77723-30-9 methyl ester O WITEGA Laboratorien Berlin-Adlershof GmbH page 4 of 104 Anthelmintica / Flukicides BI018 O Cyclopentylalbendazole (5-Cyclopentanesulfinyl-1H- 50 mg S H sulfoxide N benzoimidazol-2-yl)-carbamic acid 100 mg N O CH3 methyl ester N O H 131454-43-8 BI019 O O Cyclopentylalbendazole (5-Cyclopentanesulfo-nyl-1H- 50 mg S N sulfone H benzoimidazol-2-yl)-carbamic acid 100 mg N CH 3 methyl ester N O H O 1448346-31-3 BI032 D D Oxibendazole-amine-D7 5-Propoxy-D7-1H-benzoimidazol-2-yl- 25 mg D O N amine 50 mg D NH D D D 2 N 1448346-35-7 H BI023 O N Oxibendazole-amine 5-Propoxy-1H-benzo-imidazol-2-yl- 50 mg H C 3 NH hydrochloride 2 amine hydrochloride 100 mg N H HCl 1538624-34-8 D D BI030 O Oxibendazole-D7 (5-Propoxy-D7-1H-benzoimidazol-2-yl)- 25 mg D O O N carbamic acid methyl ester 50 mg D N CH3 D D D H N H 1173019-44-7 BI066 O CH3 Oxibendazole (5-Propoxy-1H-benzimidazol-2-yl) 100 mg O N O H3C carbamic acid methyl ester NH N 20559-55-1 H BI071 Febantel N-(2-Methoxy-acetyl-amino-4- 10 mg phenylsulfanyl-N’,N’’-bis-(methoxy- 100 mg carbonyl)-guanidine 58306-30-2 O CH Febantel-D6 BI031 O 3 N-(2-Methoxy-acetyl-amino-4- 25 mg S NH phenylsulfanyl)-N’,N”-bis-(methoxy-D3- 50 mg carbonyl)-guanidine NH O D D D HN N O D D 1173021-79-8 D O O 5-Nitrobenzimidazole BI033 O2N N 5-Nitro-1H-benzimi-dazole 50 mg 100 mg N H 94-52-0 BI039 O O Ciclobendazole (5-Cyclopropanecar-bonyl-1H- 50 mg N O Cyclobendazole benzoimida-zol-2-yl)-carbamic acid 100 mg NH CH3 methyl ester N H 31431-43-3 BI073 Levamisole (S)-6-Phenyl-2,3,5,6-tetrahydro 10 mg hydrochloride imidazo[2,1-b]thiazole hydrochloride 16595-80-5 BI040 N 4-Hydroxy-tetramisole 4-(2,3,5,6-Tetrahydro-imidazo[2,1- 25 mg HO b]thiazol-6-yl-phenol 50 mg N S WITEGA Laboratorien Berlin-Adlershof GmbH page 5 of 104 Anthelmintica / Flukicides 6649-26-9 H Cl BI041 D D Tetramisole-D5 6-Phenyl-D5-2,3,5,6-tetrahydro- 25 mg hydrochloride imidazo[2,1-b]thiazole hydrochloride N 50 mg D N S 1173021-85-6 D D BI042 N D D Carbendazim-D3 (1H-Benzoimidazol-2-yl)-carbamic acid 50 mg H N D methyl ester-D3 100 mg N O H O 1255507-88-0 BI043 I Nitroxynil 4-Hydroxy-3-iodo-5-nitro-benzonitrile 50 mg OH 100 mg NC NO 1689-89-0 2 BI044 I Nitroxynil-13C6 4-Hydroxy-3-iodo-5-nitro-benzonitrile- 25 mg 13 13 C OH C6 13C 13C 50 mg 13C 13C 1325559-31-6 NC 13C NO 2 O BI045 O Rafoxanide N-[3-Chloro-4-(4-chloro-phenoxy)- 50 mg I phenyl]-2-hydroxy-3,5-diiodo- 100 mg N Cl Cl H benzamide OH 22662-39-1 I O BI046 O Rafoxanide-13C6 N-[3-Chloro-4-(4-chloro-phenoxy)- 25 mg 13 I C phenyl]-2-hydroxy-3,5-diiodo-
Load more

Recommended publications
  • Evaluation of Fluralaner and Afoxolaner Treatments to Control Flea
    Dryden et al. Parasites & Vectors (2016) 9:365 DOI 10.1186/s13071-016-1654-7 RESEARCH Open Access Evaluation of fluralaner and afoxolaner treatments to control flea populations, reduce pruritus and minimize dermatologic lesions in naturally infested dogs in private residences in west central Florida USA Michael W. Dryden1*, Michael S. Canfield2, Kimberly Kalosy1, Amber Smith1, Lisa Crevoiserat1, Jennifer C. McGrady1, Kaitlin M. Foley1, Kathryn Green2, Chantelle Tebaldi2, Vicki Smith1, Tashina Bennett1, Kathleen Heaney3, Lisa Math3, Christine Royal3 and Fangshi Sun3 Abstract Background: A study was conducted to evaluate and compare the effectiveness of two different oral flea and tick products to control flea infestations, reduce pruritus and minimize dermatologic lesions over a 12 week period on naturally infested dogs in west central FL USA. Methods: Thirty-four dogs with natural flea infestations living in 17 homes were treated once with a fluralaner chew on study day 0. Another 27 dogs living in 17 different homes were treated orally with an afoxolaner chewable on day 0, once between days 28–30 and once again between days 54–60. All products were administered according to label directions by study investigators. Flea populations on pets were assessed using visual area counts and premise flea infestations were assessed using intermittent-light flea traps on days 0, 7, 14, 21, and once between days 28–30, 40–45, 54–60 and 82–86. Dermatologic assessments were conducted on day 0 and once monthly. Pruritus assessments were conducted by owners throughout the study. No concurrent treatments for existing skin disease (antibiotics, anti-inflammatories, anti-fungals) were allowed.
    [Show full text]
  • Historical Perspectives on Apple Production: Fruit Tree Pest Management, Regulation and New Insecticidal Chemistries
    Historical Perspectives on Apple Production: Fruit Tree Pest Management, Regulation and New Insecticidal Chemistries. Peter Jentsch Extension Associate Department of Entomology Cornell University's Hudson Valley Lab 3357 Rt. 9W; PO box 727 Highland, NY 12528 email: [email protected] Phone 845-691-7151 Mobile: 845-417-7465 http://www.nysaes.cornell.edu/ent/faculty/jentsch/ 2 Historical Perspectives on Fruit Production: Fruit Tree Pest Management, Regulation and New Chemistries. by Peter Jentsch I. Historical Use of Pesticides in Apple Production Overview of Apple Production and Pest Management Prior to 1940 Synthetic Pesticide Development and Use II. Influences Changing the Pest Management Profile in Apple Production Chemical Residues in Early Insect Management Historical Chemical Regulation Recent Regulation Developments Changing Pest Management Food Quality Protection Act of 1996 The Science Behind The Methodology Pesticide Revisions – Requirements For New Registrations III. Resistance of Insect Pests to Insecticides Resistance Pest Management Strategies IV. Reduced Risk Chemistries: New Modes of Action and the Insecticide Treadmill Fermentation Microbial Products Bt’s, Abamectins, Spinosads Juvenile Hormone Analogs Formamidines, Juvenile Hormone Analogs And Mimics Insect Growth Regulators Azadirachtin, Thiadiazine Neonicotinyls Major Reduced Risk Materials: Carboxamides, Carboxylic Acid Esters, Granulosis Viruses, Diphenyloxazolines, Insecticidal Soaps, Benzoyl Urea Growth Regulators, Tetronic Acids, Oxadiazenes , Particle Films, Phenoxypyrazoles, Pyridazinones, Spinosads, Tetrazines , Organotins, Quinolines. 3 I Historical Use of Pesticides in Apple Production Overview of Apple Production and Pest Management Prior to 1940 The apple has a rather ominous origin. Its inception is framed in the biblical text regarding the genesis of mankind. The backdrop appears to be the turbulent setting of what many scholars believe to be present day Iraq.
    [Show full text]
  • B Commission Regulation (Eu)
    02010R0037 — EN — 29.09.2018 — 035.001 — 1 This text is meant purely as a documentation tool and has no legal effect. The Union's institutions do not assume any liability for its contents. The authentic versions of the relevant acts, including their preambles, are those published in the Official Journal of the European Union and available in EUR-Lex. Those official texts are directly accessible through the links embedded in this document ►B COMMISSION REGULATION (EU) No 37/2010 of 22 December 2009 on pharmacologically active substances and their classification regarding maximum residue limits in foodstuffs of animal origin (Text with EEA relevance) (OJ L 15, 20.1.2010, p. 1) Amended by: Official Journal No page date ►M1 Commission Regulation (EU) No 758/2010 of 24 August 2010 L 223 37 25.8.2010 ►M2 Commission Regulation (EU) No 759/2010 of 24 August 2010 L 223 39 25.8.2010 ►M3 Commission Regulation (EU) No 761/2010 of 25 August 2010 L 224 1 26.8.2010 ►M4 Commission Regulation (EU) No 890/2010 of 8 October 2010 L 266 1 9.10.2010 ►M5 Commission Regulation (EU) No 914/2010 of 12 October 2010 L 269 5 13.10.2010 ►M6 Commission Regulation (EU) No 362/2011 of 13 April 2011 L 100 26 14.4.2011 ►M7 Commission Regulation (EU) No 363/2011 of 13 April 2011 L 100 28 14.4.2011 ►M8 Commission Implementing Regulation (EU) No 84/2012 of 1 L 30 1 2.2.2012 February 2012 ►M9 Commission Implementing Regulation (EU) No 85/2012 of 1 L 30 4 2.2.2012 February 2012 ►M10 Commission Implementing Regulation (EU) No 86/2012 of 1 L 30 6 2.2.2012 February 2012 ►M11 Commission
    [Show full text]
  • Identification of Transcriptome and Fluralaner Responsive Genes in The
    Jia et al. BMC Genomics (2020) 21:120 https://doi.org/10.1186/s12864-020-6533-0 RESEARCH ARTICLE Open Access Identification of transcriptome and fluralaner responsive genes in the common cutworm Spodoptera litura Fabricius, based on RNA-seq Zhong-Qiang Jia1, Di Liu1, Ying-Chuan Peng1,3, Zhao-Jun Han1, Chun-Qing Zhao1* and Tao Tang2* Abstract Background: Fluralaner is a novel isoxazoline insecticide with a unique action site on the γ-aminobutyric acid receptor (GABAR), shows excellent activity on agricultural pests including the common cutworm Spodoptera litura, and significantly influences the development and fecundity of S. litura at either lethal or sublethal doses. Herein, Illumina HiSeq Xten (IHX) platform was used to explore the transcriptome of S. litura and to identify genes responding to fluralaner exposure. Results: A total of 16,572 genes, including 451 newly identified genes, were observed in the S. litura transcriptome and annotated according to the COG, GO, KEGG and NR databases. These genes included 156 detoxification enzyme genes [107 cytochrome P450 enzymes (P450s), 30 glutathione S-transferases (GSTs) and 19 carboxylesterases (CarEs)] and 24 insecticide-targeted genes [5 ionotropic GABARs, 1 glutamate-gated chloride channel (GluCl), 2 voltage-gated sodium channels (VGSCs), 13 nicotinic acetylcholine receptors (nAChRs), 2 acetylcholinesterases (AChEs) and 1 ryanodine receptor (RyR)]. There were 3275 and 2491 differentially expressed genes (DEGs) in S. litura treated with LC30 or LC50 concentrations of fluralaner, respectively. Among the DEGs, 20 related to detoxification [16 P450s, 1 GST and 3 CarEs] and 5 were growth-related genes (1 chitin and 4 juvenile hormone synthesis genes).
    [Show full text]
  • The Effectiveness of a Pyriprole \(125 Mg/Ml\) and a Metaflumizone \(150
    Article available at http://www.parasite-journal.org or http://dx.doi.org/10.1051/parasite/2008151093 THE EFFECTIVENESS OF A PYRIPROLE (125 MG/ML) AND A METAFLUMIZONE (150 MG/ML) COMBINED WITH AMITRAZ (150 MG/ML) SPOT-ON TREATMENT IN PREVENTING PHLEBOTOMUS PERNICIOSUS FROM FEEDING ON DOGS THOMAS C.*, ROQUES M.* & FRANC M.* Summary: Résumé : PYRIPROLE ET ASSOCIATION MÉTAFLUMIZONE-AMITRAZ : ÉTUDE DE L’ACTIVITÉ ANTI-GORGEMENT VIS-À-VIS DE PHLEBOTOMUS A controlled clinical trial was performed to assess the effectiveness PERNICIOSUS SUR LE CHIEN TRAITÉ PAR CES FORMULATIONS SPOT-ON of a pyriprole (125 mg/ml) and a metaflumizone (150 mg/ml) combined with amitraz (150 mg/ml) spot-on treatment Cet essai avait pour but d’étudier l’efficacité de deux spot-on (recommended dosage) in preventing adult female sandflies destinés au chien – pyriprole (125 mg/ml) et métaflumizone (Phlebotomus perniciosus) from feeding on dogs. Sandfly mortality (150 mg/ml) associée à l’amitraz (150 mg/ml) – sur les was also assessed. Twelve beagle dogs were used in the study. phlébotomes (effet létal et effet antigorgement). 12 chiens ont été Prior to treatment they were checked for their attractiveness to sand- utilisés. Ils ont été répartis en trois lots de quatre en fonction de flies, ranked accordingly to generate partner triplets of equivalent leur attractivité pour les femelles de phlébotomes. Un lot a été sensitivity to sandflies: four control dogs, four treated with the traité avec le spot-on au pyriprole, un lot avec la métaflumizone pyriprole and four with the metaflumizone spot-on. The dogs were associée à de l’amitraz, le dernier lot étant le lot témoin non challenged with 50 unfed adult female sandflies (8-10 days old), traité.
    [Show full text]
  • Efficacy of a Fixed Combination of Permethrin 54.5% and Fipronil 6.1
    Bonneau et al. Parasites & Vectors (2015) 8:204 DOI 10.1186/s13071-015-0805-6 RESEARCH Open Access Efficacy of a fixed combination of permethrin 54.5% and fipronil 6.1% (Effitix®) in dogs experimentally infested with Ixodes ricinus Stéphane Bonneau1†, Nadège Reymond2†, Sandeep Gupta3 and Christelle Navarro1* Abstract Background: Ticks are the most important vectors of disease-causing pathogens in domestic animals and are considered to be second worldwide to mosquitoes as vectors of human diseases. In Europe, Ixodes ricinus,the sheep tick, plays an important role as companion animal parasite but is also the primary vector of medically important diseases such as tick-borne encephalitis and Lyme borreliosis. The present study was designed to evaluate the efficacy under laboratory conditions of a new fixed spot-on combination of fipronil and permethrin (Effitix®, Virbac) in treating and preventing tick infestations of Ixodes ricinus in dogs. Methods: Twelve dogs were included in this randomized, controlled, blinded laboratory study. They were randomly allocated to two groups of six dogs each according to their pre-treatment live attached Ixodes ricinus tick count. On day 0,thedogsfromGroup2weretreatedwiththerecommendeddose of Effitix®, the dogs from Group 1 remained untreated. On days −2, 7, 14, 21, 28 and 35, all dogs were infested with 50 (±4) viable unfed adult Ixodes ricinus (20 ± 2 males, 30 ± 2 females). Ticks were removed and counted at 48 ± 2 hours post product administration or tick infestations. Results: Through the study, the tick attachment rates for the untreated group were greater than 25% demonstrating that adequate levels of infestation were reached on the control dogs.
    [Show full text]
  • Evaluation of Fluralaner As an Oral Acaricide to Reduce Tick Infestation
    Pelletier et al. Parasites Vectors (2020) 13:73 https://doi.org/10.1186/s13071-020-3932-7 Parasites & Vectors RESEARCH Open Access Evaluation of furalaner as an oral acaricide to reduce tick infestation in a wild rodent reservoir of Lyme disease Jérôme Pelletier1,2,3*, Jean‑Philippe Rocheleau2,4, Cécile Aenishaenslin1,2,3, Francis Beaudry5, Gabrielle Dimitri Masson1,2, L. Robbin Lindsay6, Nicholas H. Ogden2,7, Catherine Bouchard2,7 and Patrick A. Leighton1,2,3 Abstract Background: Lyme disease (LD) is an increasing public health threat in temperate zones of the northern hemisphere, yet relatively few methods exist for reducing LD risk in endemic areas. Disrupting the LD transmission cycle in nature is a promising avenue for risk reduction. This experimental study evaluated the efcacy of furalaner, a recent oral aca‑ ricide with a long duration of efect in dogs, for killing Ixodes scapularis ticks in Peromyscus maniculatus mice, a known wildlife reservoir for Borrelia burgdorferi in nature. Methods: We assigned 87 mice to 3 furalaner treatment groups (50 mg/kg, 12.5 mg/kg and untreated control) administered as a single oral treatment. Mice were then infested with 20 Ixodes scapularis larvae at 2, 28 and 45 days post‑treatment and we measured efcacy as the proportion of infesting larvae that died within 48 h. At each infesta‑ tion, blood from 3 mice in each treatment group was tested to obtain furalaner plasma concentrations (C p). Results: Treatment with 50 mg/kg and 12.5 mg/kg furalaner killed 97% and 94% of infesting larvae 2 days post‑treat‑ ment, but no signifcant efect of treatment on feeding larvae was observed 28 and 45 days post‑treatment.
    [Show full text]
  • Draft Product Performance Test Guidelines OCSPP 810.3300
    United States Office of Chemical Safety EPA 712-[insert number] Environmental Protection and Pollution Prevention [DRAFT DATE 4/4/19] Agency (7101) Draft Product Performance Test Guidelines OCSPP 810.3300: Treatments Topically Applied to Pets to Control Certain Invertebrate Ectoparasitic Pests NOTICE This guideline is one of a series of test guidelines established by the Office of Chemical Safety and Pollution Prevention (OCSPP) [formerly the Office of Prevention, Pesticides and Toxic Substances (OPPTS) prior to April 22, 2010], United States Environmental Protection Agency (US EPA) for use in testing pesticides and chemical substances to develop data for submission to the agency under the Toxic Substances Control Act (TSCA) (15 U.S.C. 2601, et seq.), the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA) (7 U.S.C. 136, et seq.), and section 408 of the Federal Food, Drug and Cosmetic (FFDCA) (21 U.S.C. 346a), referred to hereinafter as the harmonized test guidelines. The OCSPP test guidelines serve as a compendium of accepted scientific methodologies for research intended to provide data to inform regulatory decisions under TSCA, FIFRA, and/or FFDCA. This document provides guidance for conducting appropriate tests, and is also used by EPA, the public, and the companies that are required to submit data under FIFRA. These guidelines are not binding on either EPA or any outside parties, and the EPA may depart from them where circumstances warrant and without prior notice. The methods described in these guidelines are strongly recommended for generating the data that are the subject of the guidelines, but EPA recognizes that departures may sometimes be appropriate.
    [Show full text]
  • Chemotherapeutants Against Salmon Lice Lepeophtheirus Salmonis – Screening of Efficacy
    Chemotherapeutants against salmon lice Lepeophtheirus salmonis – screening of efficacy Stian Mørch Aaen Thesis for the degree of Philosophiae Doctor Department of Food Safety and Infection Biology Faculty of Veterinary Medicine and Biosciences Norwegian University of Life Sciences Adamstuen 2016 1 2 TABLE OF CONTENTS Acknowledgments 5 Acronyms/terminology 7 List of papers 8 Summary 9 Sammendrag 9 1 Introduction 11 1.1 Salmon farming in an international perspective; industrial challenges 11 1.2 Salmon lice 12 1.2.1 History and geographic distribution 12 1.2.2 Salmon lice life cycle 14 1.2.3 Pathology caused by salmon lice 16 1.2.4 Salmon lice cultivation in the lab 16 1.3 Approaches to combat sea lice 17 1.3.1 Medicinal interference: antiparasitic chemotherapeutants 17 1.3.2 Resistance in sea lice against chemotherapeutants 19 1.3.3 Non-medicinal intervention: examples 22 1.3.3.1 Physical barriers 23 1.3.3.2 Optical and acoustic control measures 23 1.3.3.3 Functional feeds, vaccine, breeding 24 1.3.3.4 Biological de-lousing: cleaner fish and freshwater 24 1.3.3.5 Physical removal 24 1.3.3.6 Fallowing and geographical zones 25 1.4 Rationale 25 2 Aims 26 3 Materials and methods 26 3.1 Materials 26 3.1.1 Salmon lice 26 3.1.2 Fish – Atlantic salmon 26 3.1.3 Water 27 3.1.3 Medicinal compounds 27 3.1.4 Dissolvents 29 3.2 Methods 29 3.2.1 Hatching assays with egg strings 29 3.2.2 Survival assays with nauplii 29 3.2.3 Bioassays with preadults 30 3.2.4 Statistical analysis 31 4 Summary of papers, I-IV 32 5 Discussion 35 5.1 Novel methods for medicine screening 35 5.2 Industrial innovation in aquaculture and pharmaceutical companies 35 5.3 Administration routes of medicinal compounds to fish 36 5.4 Mixing and bioavailability of medicinal products in seawater 37 5.5 Biochemical targets in L.
    [Show full text]
  • Cover Memo Isoxazolines Inquires
    Name: Isoxazoline inquiries DATE:10/1/2018 This serves as the response to your Freedom of Information Act (FOIA) request for records regarding adverse event reports received for afoxolaner, fluralaner, lotilaner and sarolaner. A search of CVM’s Adverse Drug Event (ADE) database was performed on 10-01-2018. The search parameters were: Active ingredient(s): afoxolaner, fluralaner, lotilaner and sarolaner Reports received: From 09-04-2013 through 07-31-2018 Case type: Spontaneous ADE report Species: All Route of administration: All For each drug (active ingredient), we have provided the ‘CVM ADE Comprehensive Clinical Detail Report Listing’, which is a cumulative listing of adverse experiences in reports submitted to CVM. General Information about CVM’s ADE Database The primary purpose for maintaining the CVM ADE database is to provide an early warning or signaling system to CVM for adverse effects not detected during pre-market testing of FDA- approved animal drugs and for monitoring the performance of drugs not approved for use in animals. Information from these ADE reports is received and coded in an electronic FDA/CVM ADE database. CVM scientists use the ADE database to make decisions about product safety which may include changes to the label or other regulatory action. CVM’s ADE reporting system depends on detection and voluntary reporting of adverse clinical events by veterinarians and animal owners. The Center's ADE review process is complex, and for each report takes into consideration confounding factors such as: Dosage Concomitant drug use The medical and physical condition of animals at the time of treatment Environmental and management information Product defects Name: Isoxazoline inquiries DATE:10/1/2018 Extra-label (off label) uses The specifics of these complex factors cannot be addressed in the CVM ADE Comprehensive Clinical Detail Report Listing.
    [Show full text]
  • Preventing Unsafe Chemicals in Food Using Triple Quadrupole LC/MS
    WWW.FOODQUALITYANDSAFETY.COM You Are What You Eat Preventing Unsafe Chemicals In Food Using Triple Quadrupole LC/MS Sponsored by: Unbelievably Robust, Remarkably Versatile Trying to keep up with growing demands and challenges in the lab can be an overwhelming task. At Agilent, we are consistently innovating to help you meet those needs. We’ve taken the trusted 6470A LC/TQ and added some new features to this workhorse. The 6470B LC/TQ is enhanced to maximize productivity with new technology for reduced downtime. Now you don’t have to choose between rock-solid performance and flexibility. Visit www.agilent.com/chem/6470B © Agilent Technologies, Inc. 2021 Contents From The Editor www.foodqualityandsafety.com By Samara E. Kuehne esticide residues that remain in or on vegetables, 3 fruits, herbs, honey, oil, seeds, and food of animal From the Editor Porigin can pose major threats to human health and to the environment. Improperly used veterinary drugs BY SAMARA E. KUEHNE and antibiotics can accumulate in food derived from animals, which can also adversely affect consumers. 4 Additionally, mycotoxins, produced primarily by the As- pergillus, Penicillium, and Fusarium fungi, have the po- Comprehensive LC/MS/MS Workflow of tential to contaminate a variety of common foods, such Pesticide Residues in High Water, High Oil, as grains, nuts, cocoa, and milk, and present an ongoing and High Starch Sample Matrices Using the challenge to food safety all along the food chain. Agilent 6470 Triple Quadrupole LC/MS System Limiting exposure to these potentially life-threatening contaminants in food and animal feed is critically im- BY AIMEI ZOU, SASHANK PILLAI, PETER KORNAS, MELANIE SCHOBER, portant.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,139,481 B2 Sanders (45) Date of Patent: Sep
    US009139481 B2 (12) United States Patent (10) Patent No.: US 9,139,481 B2 Sanders (45) Date of Patent: Sep. 22, 2015 (54) ANHYDROUS AMMONIA SUPPLEMENTED 3,796.559 A * 3/1974 Windgassen ........................ 71/1 WITH AGRICULTURAL ACTIVES 3,997,319 A 12/1976 Ott 4,007,029 A * 2/1977 Kenton ............................. T1/11 (71) Applicant: Specialty Fertilizer Products, LLC, 5,210,163 A 5, 1993 Grey Leawood, KS (US) 5,536.311 A 7/1996 Rodrigues s 6,228.806 B1* 5/2001 Mehta ........................... 504,117 6,515,090 B1 2/2003 Sanders et al. (72) Inventor: John Larry Sanders, Leawood, KS 6,632,262 B2 * 10/2003 Gabrielson ....................... T1/30 (US) 7,655,597 B1 2/2010 Sanders 8,043,995 B2 10/2011 Sanders et al. (73) Assignee: Verdesian Life Sciences, LLP, Cary, 8,491,693 B2 * 7/2013 Burnham .......................... T1/11 NC (US) 2004/0211234 A1* 10/2004 Volgas et al. .................. 71 (64.1 2009/0071213 A1 3/2009 Keenan et al. (*) Notice: Subject to any disclaimer, the term of this 2009/0163365 A1 6/2009 Bentlage et al. patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. FOREIGN PATENT DOCUMENTS (21) Appl. No.: 14/285,272 RU 2051884 C1 1, 1996 (22) Filed: May 22, 2014 OTHER PUBLICATIONS (65) Prior Publication Data International Search Report and Written Opinion dated Oct. 16, 2014 in PCT/US 2014/039424, International Filing Date: May 23, 2014. US 2014/0345344 A1 Nov. 27, 2014 U.S. Appl. No. 62/001,110, filed May 21, 2014, entitled Polyanionic Related U.S.
    [Show full text]